Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Verda J. Hunter"'
Publikováno v:
Journal of the American College of Nutrition. 22:118-123
Objective: Because of poor overall survival in advanced ovarian malignancies, patients often turn to alternative therapies despite controversy surrounding their use. Currently, the majority of cancer patients combine some form of complementary and al
Autor:
Verda J. Hunter, David S. Alberts, Amy Tiersten, S. Weiner, Poching Liu, Peter C. Kohler, Edward V. Hannigan, Sharon P. Wilczynski, Mace L. Rothenberg, Geoffrey R. Weiss, Julia Chapman
Publikováno v:
Gynecologic Oncology. 82:317-322
Objective. The aim of this study was to evaluate the 2-year survival rate in a group of women in complete clinical remission (cCR) from Stage III ovarian cancer following front-line therapy who were then treated with a 6-month course of altretamine.
Publikováno v:
Experimental Biology and Medicine. 209:325-342
Tumor necrosis factor-alpha (TNF), originally identified as an inflammation-associated cytokine, is synthesized throughout the female reproductive tract as well as in placentas and embryos. Development, female sex steroid hormones, and lipopolysaccha
Autor:
John T. Soper, Verda J. Hunter, Mary Tanner, Daniel L. Clarke-Pearson, Lee Daly, Fred Tyson, Robert C. Bast, Kathy O'Briant, Nick Chrysson, Andrew Berchuck, Stephen L. George, Wesley C. Fowler
Publikováno v:
Gynecologic Oncology. 45:299-302
Unusual restriction fragment length polymorphisms (RFLPs) of the Ha-ras locus have been found in DNA from leukocytes and tumor tissue of cancer patients. To determine whether rare alleles would be observed frequently in patients with ovarian cancer,
Autor:
John T. Soper, Lee Daly, Robert C. Bast, Michael J. Helms, Andrew Berchuck, Verda J. Hunter, Daniel L. Clarke-Pearson
Publikováno v:
American Journal of Obstetrics and Gynecology. 163:1164-1167
Fifty-four patients with advanced epithelial ovarian cancer were monitored with serial serum CA 125 levels after surgical cytoreduction and during multi-agent chemotherapy with cisplatin-containing regimens. CA 125 half-life of less than 20 days was
Autor:
Neal M. Lonky, Juan C. Felix, Jay Carlson, L. Stewart Massad, Christopher P. Crum, Verda J. Hunter, Burton A. Krumholz, Luis A Padilla-Paz, J. L. Benedet, Leo B. Twiggs
Publikováno v:
Journal of lower genital tract disease. 8(2)
Objective The study was undertaken to provide consensus guidelines for the management of women with a cytologic interpretation of high-grade squamous intraepithelial lesion (HSIL) on cytologic examination. This review article presents relevant litera
Publikováno v:
Gynecologic oncology. 88(3)
Objective At the present time, many cancer patients combine some form of complementary and alternative medicine therapies with their conventional therapies. The most common choice of these therapies is the use of antioxidants. Results A review of fou
Autor:
Maria Sancho-Tello, Verda J. Hunter, Jennifer L. Marcinkiewicz, Paul F. Terranova, Bruce F. Kimler, William M. Justice
Publikováno v:
American journal of obstetrics and gynecology. 173(5)
OBJECTIVE: Our purpose was to determine the ability of an ovarian epithelial carcinoma cell line, Caov-3, to alter the bioactivity of exogenously added tumor necrosis factor-α. STUDY DESIGN: Caov-3 cells were cultured for up to 6 days in Dulbecco's
Publikováno v:
Fertility and sterility. 59(2)
Objective To determine if tumor necrosis factor α (TNF- α ) altered human granulosa-luteal cell proliferation and steroidogenesis. Design Aspirates of follicles from women undergoing in vitro fertilization were subjected to Percoll gradients to col
Autor:
Robert C. Knapp, L. Metsch, J. B. Weinberg, Arthur F. Haney, Verda J. Hunter, Philip T. Lavin, Robert C. Bast, John T. Soper
Publikováno v:
Gynecologic oncology. 36(2)
CA 125 was measured in peritoneal fluid from 200 patients with primary ovarian malignancies (35) and benign gynecologic conditions (165). In 86 patients CA 125 was measured both in peritoneal fluid and in serum. Patients with ovarian cancer had marke